Canada: Pharmacapsules@Gowlings - December 20, 2007

Last Updated: January 21 2008

Edited by Jennifer Wilkie and Chantal Saunders


  • Biomara Moving To The United States
  • Report On The Statutory Review Of Sections 21.01 To 21.19 Of The Patent Act (Access To Medicines) Released
  • Free Trade Zones Facilitate Counterfeit Drug Trade
  • Prescription Drug Advertising Update
  • Parliamentary Committee Calls For Improvements To The Common Drug Review Process
  • Recent Cases
Biomara Moving To The United States

In its 2007 "Mobilizing Science and Technology to Canada's Advantage" Report (the "Report"), the Federal Government recognizes the importance of building a strong science and technology infrastructure to improve Canada's competitiveness and productivity. The Report acknowledges that while Canada has tremendous strengths, it also faces numerous challenges which need to be addressed comprehensively to enable the country to continue to build a competitive and sustainable economy. The Report sets out a strategy involving greater private sector investment, world-class research excellence and attracting, retaining and developing talented, skilled and creative people in the science and technology disciplines.

The Canadian government must be somewhat dismayed by Edmonton-based Biomara Inc.'s recent decision to move the company to the US and to establish new headquarters in the Seattle area. Biomara, which is listed on the Toronto Stock Exchange in Canada and on NASDAQ in the US, is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. It has just under 80 employees, most of whom are based in Edmonton. From a financial perspective, Biomara is not particularly significant, with revenues of just over $4 million and net losses in the last two years of $18 million and $19 million. In 2007, its stock price slumped to under $1.00, resulting in NASDAQ threatening to delist the company.

However, Biomara is also Alberta's oldest biotech company, formed in 1985 as a spin-off from the University of Alberta. It has been estimated that more that $300 million of capital has been invested into the company over the years.

Biomara, which is changing its name to Oncothyreon, stated that its move out of Canada is designed to raise its profile in US financial markets and provide access to a larger pool of investment capital. While the company did advise that the relocation of Biomara's headquarters to Seattle is not expected to result in a significant change in its Edmonton operations, its CEO stated that moving to a major biotechnology hub such as Seattle will provide greater opportunity to attract and retain key personnel.

A sceptic might suggest that Biomara's decision to leave Canada was influenced by the fact that its recently-appointed CEO is from the Seattle area and that its new Chairman of the Board is also based in the US.

Nonetheless, Biomara's move highlights the importance of Canada executing as quickly as possible on the Report's strategies. In particular, the issue of increasing private sector investment in science and technology, and finding structures and incentives that can increase financial contributions by the private sector, must be addressed. A vibrant, sustainable and competitive science and technology sector in Canada requires no less.

For more information, please see:
By: Michael Herman

Report On The Statutory Review Of Sections 21.01 To 21.19 Of The Patent Act (Access To Medicines) Released

The CAMR report was released on December 14, 2007. In essence, the report does not suggest fundamental change. The report concludes that insufficient time has passed and insufficient evidence has accumulated since the coming into force of CAMR to warrant legislative changes to the regime. The conclusion is that the Government should focus on non-legislative measures to improve access to medicines in the developing world, until a more definitive assessment can be made (p. 7).

Summary of input from review deals with the following issues, but does not make specific recommendations; the report outlines the positions of those who submitted comments on these topics:

  1. Eligible importers
  2. Eligible pharmaceutical products
  3. Health Canada's Drug Review
  4. Application process
  5. Voluntary licence request
  6. Duration of licence
  7. Royalties paid to patent holders
  8. The good faith clause
  9. Quantities exported
  10. Anti-diversion measures
  11. Termination of licence

Other considerations were noted. These included a discussion of the following topics:

  • Global burden of HIV/AIDS, tuberculosis and malaria
  • International initiatives and partnerships
  • Country based initiatives
  • ARV therapies as a model to treat HIV/AIDS

In the Analysis section, the report notes that there are a number of WTO members that have amended their laws, but that no two regimes are perfectly aligned and CAMR contains a number of measures that have not been emulated elsewhere. These include reliance on pre-approved lists of products and countries, and the grant of a licence being contingent upon the health and safety review of the product. Also, whereas many other regimes waive the requirement for a voluntary licence request, in cases of national emergency, CAMR does not (p. 29).

It is noted that divergent approaches can be equally compliant with the TRIPs obligations. There are operational advantages to scheduling of products and countries. The process is clarified and expedited, with minimal discretion of the Commissioner, and the outcomes are far less vulnerable to legal challenge. The Apotex licence is noted, and specifically, the fact that the licence was granted less than three weeks after the paperwork was filed. However, it is noted that the schedules require regular upkeep. It remains to be seen if the intended operational advantages outweigh the drawback in time and resources required to maintain them.

Similar reasoning was applied to the requirement for health review of exported products by Health Canada.

The report notes that the voluntary licence requirement is more complex. Canada believed it was necessary. The extent to which this is consistent with Article 31(b) remains the subject of debate. Even if this aspect were eliminated, notification of the importing country remains a requirement. The Apotex example is noted, and, in respect of the requirement for a voluntary licence stage, it was noted that "To the extent that one can assert that there was a delay between these two steps, it was relatively insignificant." (at page 32, in speaking of the voluntary licence and compulsory licence stages).

The report states at page 35 as follows:

"In light of all of the above, the view that certain unique feature of CAMR make it less permissive or operationally sound than the legislation subsequently adopted in other countries to have implemented the waiver does not appear to be substantiated by the available evidence at this juncture. While there may be room to improve CAMR, as there is with any legal framework, more time, evidence and analysis is needed to determine if changes to these features, along the lines of the amendments proposed by various stakeholder groups, would make a meaningful difference in the volume and frequency of exports...'

'Furthermore for the moment at least, the granting of the first and only export licence under the waiver to Apotex, and the circumstances surrounding it, suggest that CAMR works reasonably well and quickly, provided an importing country has made the requisite notification to the WTO. "

In conclusion, the report notes that more could be done to address the underlying economic barriers and will undertake further analysis of this issue, once greater experience with the waiver is gained. Outreach on awareness, and other initiatives, such as the Budget 2007 new tax incentive to encourage pharmaceutical donations are noted. Direct governmental targeted initiatives in providing medicines and vaccines to developing countries were also noted.

For more information, please see:
By: Adrienne Blanchard

Free Trade Zones Facilitate Counterfeit Drug Trade

A set of articles by investigative reporter Walt Bogdanich published in the New York Times and the International Herald Tribune on December 17, 2007 describe how international free trade zones such as those in the United Arab Emirates, Jordan, Mauritius and Panama are easing the passage of counterfeit drugs. Experts cited in the articles indicated that counterfeiters use free trade zones to hide or sanitize a drug's provenance or to make, market or re-label adulterated products. Indeed, according to Ilisa Bernstein, Director of Pharmacy Affairs at the U.S. Food and Drug Administration: "free trade zones allow counterfeiters to evade the laws of the country because often times the regulations are law in these zones." This is because most shipments of goods that go through free trade zones do not officially enter the country where the zone is located, and are therefore subject to fewer bureaucratic entanglements and regulation. In addition, counterfeiters can use the zones as a way to hide where their products are originally sourced. The articles singled out Dubai as a free trade zone that is particularly attractive to counterfeiters because (a) of its strategic location; (b) of the high volume of goods that move through it; and (c) there is some confusion as to whether normal Dubai customs have jurisdiction in the free trade zones although the authorities in Dubai have shown a willingness to act when drug company investigators tip them to possible counterfeits. According to the articles, nearly a third of all counterfeit drugs confiscated in Europe in 2006 came via the United Arab Emirates.

For more information, please see:
By: Isabel J. Raasch

Prescription Drug Advertising Update

Health Canada has recently clarified its position with respect to using prescription drug package representations in drug reminder and help-seeking advertisements directed to consumers. With respect to reminder advertisements, Health Canada has traditionally taken the position that reminder advertisements, where the name of a prescription drug is mentioned without reference to a disease state, does not go beyond the name, price and quantity restrictions outlined in the Food and Drug Regulations. With respect to help-seeking advertisements, where a disease state is discussed, but no reference is made to a specific prescription drug product, Health Canada has taken the position that such advertisements are not considered product advertisements pursuant to the Health Canada policy "The Distinction Between Advertising and Other Activities".

Health Canada has clarified its position, so that the depiction of easily recognizable branded product packages in a manner that the prescription drug indications can be identified by the consumer, would go beyond the name, price and quantity restrictions outlined in the Food and Drug Regulations.

For a copy of the Marketed Health Products Directorate Notice, please see:
By: Lewis Retik

Parliamentary Committee Calls For Improvements To The Common Drug Review Process

The House of Commons Standing Committee on Health has released its report on the Common Drug Review (CDR), the federal/provincial/territorial process to review the clinical efficacy and cost effectiveness of new drugs for purposes of recommending coverage under 18 public drug programs across Canada, except in Québec. In hearings conducted last spring, the committee heard from all major stakeholders including federal and provincial governments, the pharmaceutical industry, patient advocacy groups, and officials from the Canadian Agency for Drugs and Technologies in Health (CADTH) which is responsible for the delivery of the CDR.

Although the Standing Committee considers the CDR to be "a good start" and notes that participating drug plans look upon it favourably, it also expressed strong agreement with the views of other stakeholders that further improvements are necessary. In particular, the Committee calls for increased transparency and greater public involvement in the CDR, the introduction of an appeal process, and specific approaches to review drugs for rare disorders and first-in-class medicines.

For a more complete summary of the report, please visit Drug Pricing & Reimbursement @ Gowlings: Htmfiles/V1N21_20071213.en.html

For a copy of the report of the Standing Committee on Health, please visit:
By: Wayne Critchley

Recent Cases
Shire Biochem Inc. v. Canada; Janssen-Ortho Inc. v. Canada; December 13, 2007, Judicial Review of a PMPRB decision; Adderall XR®, Concerta®

The Court reasoned that because the Patent Act defines the patentee as the person entitled to the benefit of the patent for that invention, and because the Patent Act provides the ability to sue for reasonable compensation from the time the patent application is laid open, once the patent is granted a patentee is entitled to the benefit of the patent from the date the patent application was laid open. Therefore, since the patentee enjoys the patent rights from the time a patent is laid open, once it issues, then the patentee is deemed by the Patent Act to enjoy those rights as a patentee and must be taken to have sold medicines "while a patentee" and as a person entitled to the benefits of the patent during that time.

Thus, the Board was correct in deciding that it was Parliament's intent that the Board's jurisdiction over the prices for medicine should extend to the period between the laid open date and the grant of the patent, provided that the patent is granted. The Board cannot review prices during the laid open period until a patent has granted.

The Court rejected arguments that this interpretation of the Act was retrospective or ultra vires the power of Parliament.

The full text of this decision can be found at:

Abbott Laboratories Limited et al. v. The Minister of Health et al. December 7, 2007, Interlocutory Motion On The 55.2 Proceeding; Lansoprazole

In this decision, the Court again dismissed a motion by an innovator to reverse the order of evidence in a 55.2 proceeding. The innovator relied on what it alleged were unique circumstances in this case, namely that this proceeding will re-litigate the issue of infringement. Abbott alleged that Novopharm must have better evidence and an explanation for not initially putting forward its best case in the previous litigation, thus Novopharm should file its evidence first.

The Court found that although it had the jurisdiction to reverse the order of evidence, this was not a case where the circumstances to do so were appropriate. Because the Court considers that multiple NOC proceedings may proceed on an infringement issue where there are significant differences in the formulations found in the respective Notices of Allegation, the circumstances of this case are not unique. The generic company will describe the proposed use and it is incumbent on the innovators to show how that use will infringe the patent. To the extent that there are issues regarding whether the new formulation is a significant change or whether the generic company put its best foot forward, these matters are more appropriately dealt with by the trial judge hearing the proceeding.

The full text of the decision can be found at:
By: Beverley Moore

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.